MyoPi Spectacle Lenses: Reading a 12-Month Trial Through Axial Length

Jagrut Lallu — BOptom (Hons), MSc Specialty Lenses (Hons), FIAOMC. Therapeutic Optometrist & Contact Lens Specialist. Founder, New Zealand Eye Research Centre; Partner, Rose Optometry; WCO Asia-Pacific Myopia Ambassador; International Myopia Institute NZ Ambassador; Clinical Senior Lecturer, Deakin School of Optometry; Honorary Teaching Fellow, University of Auckland.
New myopia-control spectacle designs are arriving faster than the evidence behind them. MyoPi uses a continuous free-form surface rather than the rings or lenslets of earlier designs. Ye and colleagues have published a 12-month randomised trial in Ophthalmology Science, and I have read the full text. What makes it worth a close look is that its primary endpoint is axial length (how much the eye physically grows), not just the change in glasses prescription.
How the trial was run
The study randomised 116 children aged 8 to 13 at three hospital centres in China, 58 to MyoPi and 58 to ordinary single-vision spectacles. Children had cycloplegic spherical equivalent refraction between −0.75 and −5.00 D and had not had previous myopia control. At 12 months, 53 of 58 (91.4%) MyoPi children and 55 of 58 (94.8%) control children completed follow-up.
The MyoPi lens carries 2,345 small optical perturbation units arranged in 469 repeating groups, layered over the distance prescription so that the wearer sees through a continuously varying mix of defocus. Children were encouraged to wear their glasses at least 8 hours a day; self-reported wear averaged 12.41 hours a day with MyoPi and 12.19 hours with single-vision lenses. Children and parents were masked to group, but the examiners were not formally masked. Axial length was measured with an IOLMaster 500, and refraction was measured objectively after 1% cyclopentolate drops.
Why axial length matters more than the prescription
Refraction is what families notice, but it is indirect: it shifts with focusing effort, how well the drops relax focusing, and changes at the front of the eye. Axial length is the structural change linked to later risk of myopic maculopathy and retinal detachment. We explain the instruments and endpoints we rely on in our post on eye research equipment and myopia endpoints.
What the trial found
After adjustment for age, sex, centre and baseline values, eyes in the MyoPi group grew 0.19 ± 0.02 mm over 12 months, compared with 0.35 ± 0.02 mm with single-vision lenses (mean ± standard error). The between-group difference was −0.16 mm (95% CI, −0.20 to −0.12; P < 0.001). Refraction told the same story: −0.37 ± 0.04 D versus −0.75 ± 0.04 D, a difference of 0.38 D (95% CI, 0.27 to 0.49; P < 0.001).
In plain terms, the 95% confidence interval is the range of true effects that fits the data reasonably well. Here, even the least favourable end of the range (−0.12 mm) still favours MyoPi. The P-value estimates how likely a difference this large would be if the lens truly did nothing; below 0.001 means that is very unlikely.
Put simply, MyoPi eyes grew a little over half as much as control eyes. It slowed growth; it did not stop it. In an exploratory responder analysis, 28 of 53 MyoPi children (52.8%) grew 0.20 mm or less, against 15 of 55 controls (27.3%). Only 4 of 53 (7.5%) MyoPi children showed no axial growth at all. Younger children appeared to gain more (8 to 9 year olds: 0.23 ± 0.15 mm versus 0.46 ± 0.19 mm, right eyes), but these exploratory figures were not adjusted for multiple comparisons.
Visual comfort and safety
Adverse events were reported in 17 of 57 (29.8%) MyoPi children and 14 of 57 (24.6%) controls, with no serious adverse events or device faults. Best-corrected acuity stayed stable, and no child lost two lines or more. The symptom questionnaire was mixed: at 6 months, image-size distortion was reported by 15 of 57 (26.3%) MyoPi wearers versus 6 of 56 (10.7%) controls, while other items, such as seeing double images at 3 months (1.8% versus 12.3%), favoured MyoPi. The questionnaire was not an externally validated instrument, and the item-by-item tests were not corrected for multiplicity.
Who paid for it
The disclosures are worth reading precisely. The trial "received trial-related support under a research agreement with Medke Technology Co, Ltd", the lens manufacturer, "including provision of MyoPi spectacle lenses and study-related expenses". Provincial research grants from Shaanxi also contributed, and a contract research organisation provided monitoring. The authors declare no proprietary or commercial interest and state that the manufacturer did not take part in the final analysis, interpretation, drafting or the decision to publish. That arrangement is reasonable, but it is still context readers deserve, as we discuss in our post on conflicts of interest in myopia control trials.
How it fits alongside other options
The authors themselves caution that these results apply to MyoPi, not to defocus spectacle lenses as a class. There was no head-to-head comparison with established designs, and control-group progression differs between trials, so lining up effect sizes across studies is unreliable. For how one established lens compared with low-dose atropine over two years, see our review of the DIMS lenses versus 0.01% atropine trial. Choroidal thickness was also measured; the mean change did not differ between groups (difference 4.64 µm; 95% CI, −5.02 to 14.30; P = 0.342). Our post on measuring choroidal thickness explains why that marker remains exploratory.
Limitations of this evidence
- Follow-up was 12 months, so durability and any change after stopping are unknown.
- The design was single-masked; examiners were not formally masked, leaving some risk of assessment bias.
- Missing primary data were imputed by last observation carried forward.
- Wear time relied on recall by children and parents, not diaries or sensors.
- All participants were from three centres in China; results may not transfer directly to New Zealand children.
- The lens manufacturer supplied lenses and covered study-related expenses.
What this means for families
This is a well-structured trial with a clear 12-month axial length benefit and no signal of serious harm, but it is an early chapter. Before treating it as equivalent to lenses with multi-year data, I would want longer follow-up and independent replication beyond China. Lens choice should still be guided by a child's age, rate of axial growth, and what they will realistically wear every day. For a contact lens option with longer published follow-up, see our review of the MiSight 1 day evidence.
About the New Zealand Eye Research Centre
The New Zealand Eye Research Centre is an independent clinical research centre at 37 Lake Road, Frankton, Hamilton 3204. It conducts and reviews eye research with a team trained in Good Clinical Practice (GCP). Enquiries can be sent to research@nzerc.com. Clinicians can read how to refer a patient to eye research, and families can read what taking part in eye research involves.
Clinical care
Myopia management in Hamilton is provided at Rose Optometry, 38 Lake Road, by optometrists Jagrut Lallu, Jacqueline Rowe, Emilie Lawson, Jason Shen and Stella Wong. The author is a partner in the practice. Information on myopia control at Rose Optometry is on the practice website, and families can book a free Myopia Chat with the team to talk through the evidence.
How to cite this article
Lallu J. MyoPi Spectacle Lenses: Reading a 12-Month Trial Through Axial Length. New Zealand Eye Research Centre; 21 November 2026. Available at: https://www.newzealandeyeresearch.com/post/myopi-spectacle-lenses-12-month-axial-length-trial.
References
- Ye L, et al. Twelve-Month Efficacy and Visual Tolerability of MyoPi Spectacle Lenses in Childhood Myopia: A Randomized Clinical Trial. Ophthalmology Science. 2026. PMID 42960268. doi:10.1016/j.xops.2026.101407





